MAPK3 and breast cancer: Unexpectedly, silencing of PTPRE expression in human breast cancer cells has been shown to abolish ERK1/2 activation, leading to significantly diminished pERK levels [18] and siPTPRE-transfected thyroid cancer cells likewise exhibited decreased pERK1/2 levels [30].